GlobeNewswire Inc | Nov 30, 2020 07:00AM EST

November 30, 2020

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Companys Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 1141638. A live webcast of the presentation will be available on the Events and Presentations page in the Investors section of the Companys website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Companys website for 90 days following the presentation.

About IGM Biosciences, Inc.Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot PartnersDavid Pitts212-600-1902igmbio@argotpartners.com